Breaking News

Thermo Fisher Forms Cancer Immunotherapy Consortium

Aims to drive adoption of next-generation sequencing research to identify prognostic biomarkers

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Thermo Fisher Scientific has formed an Immuno-Oncology Consortium to drive adoption of highly sensitive, next-generation sequencing (NGS) clinical research panels to help identify predictive and prognostic biomarkers associated with cancer immunotherapy. The company has also launched the Ion AmpliSeq Immune Repertoire Assay Plus, TCR beta and expanded its portfolio of liquid biopsy assays for analysis of cell-free nucleic acid (cfNA) in lung and breast cancer.   Led in collaboration with Dr. S...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters